RWM
SMMT icon

Rialto Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Rialto Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.78K Buy
+396
New +$7.02K ﹤0.01% 693
2026
Q1 		– Sell
-29
Closed -$508 – 1796
2025
Q4 		$508 Buy
+29
New +$546 ﹤0.01% 1268
2025
Q3 		– Sell
-20
Closed -$426 – 1780
2025
Q2 		$426 Buy
+20
New +$456 ﹤0.01% 1216

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Rialto Wealth Management's SMMT Position: Q2 2026 in Review

Rialto Wealth Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 396 shares worth $5.78K. The stake represents ﹤0.01% of the portfolio and ranks #693 among its holdings. This is a return to the name: Rialto Wealth Management previously reported a position in SMMT as recently as Q4 2025.

Rialto Wealth Management first reported a position in SMMT in Q2 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Rialto Wealth Management held 396 shares of Summit Therapeutics worth $5.78K as of Q2 2026.
  • Summit Therapeutics was a new Rialto Wealth Management position in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #693 holding.
  • Rialto Wealth Management first reported a position in Summit Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.